Hanmi, which failed to enter the market for Vildagliptin through so-called split indications, has obtained item approval again. The MFDS approved Vildagle Tab 50mg (Vildagliptin HCl) by Hanmi on the 10th. It was licensed in January of last year, and Vildagle Tab 50mg, which was voluntarily withdrawn in July of that year.

The withdrawn item is used as an adjunct to diet and exercise therapy to improve blood sugar control in type 2 diabetes patients. It was approved for four types of treatment: ▲ single therapy ▲ Metformin combination therapy ▲ Sulfonylurea and Metformin combination therapy ▲ Insulin alone or Metformin combination therapy.

However, in addition to the four methods of use